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Abstract- We investigated the effects of 25Mg-Porphyrin-Fullerene nanoparticles, (25MgPMC16) smart 
ferroporphyrin nanoparticles, on PC12 cells exposed to oxygen-glucose deprivation/reperfusion. In order to 
explore its effect on cells under oxygen-glucose deprivation conditions, the cultures were pretreated with 
25MgPMC16 24 hours prior to oxygen-glucose deprivation/reperfusion. To initiate the oxygen-glucose 
deprivation/reperfusion, the cell culture medium was replaced with a glucose-free medium and the cells were 
transferred to a humidified incubation chamber in a mixture of 95% N2 and 5% CO2 at 37° C for 30, 60 and 
120 min. Cell viability was assessed by MTT assay. Exposure of PC12 cells to 30, 60 and 120 min oxygen-
glucose deprivation significantly decreased the cell viability. Pretreatment of the cultures with 25MgPMC16 
significantly increased cell viability in a concentration-dependent manner. Pretreatment, the cultures with 
MK-801 (10 µM), a non-competitive NMDA antagonist, has attenuated the cell death after 30 min oxygen-
glucose deprivation. We concluded that 25MgPMC16 could protect PC12 cells against oxygen-glucose 
deprivation/reperfusion-induced cell injury in a concentration-dependent manner. That could be due to the 
effect of 25MgPMC16 on ATP synthesis and the antioxidant effects of its components. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
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Introduction 
 
     A continuous blood flow to the brain supplies its 
need to oxygen and glucose. During the brain ischemia, 
an interruption in oxygen and glucose delivery causes a 
rapid reduction in energy available and thus, decreased 
ATP concentration. Therefore, it causes accumulation of 
the extracellular glutamate. Elevation in the extracellular 
glutamate levels induces a complex sequence of events 
that ultimately leads cell death (1,2). 
Glutamate is the dominant excitatory 
neurotransmitter in the mammalian central nervous 
system and is involved in important neurophysiological 
functions including cognition, memory and learning 
(3,4). The healthy adult brain has the ability to clear 
extracellular glutamate by cellular glutamate uptake 
systems. During the brain ischemia, an impairment of 
glutamate uptake causes glutamate efflux to the 
extracellular space. The abnormally release of glutamate 
can cause neuronal cell death by a pathological process 
known as glutamate excitotoxicity (5-8). In 
physiological conditions, magnesium is a 
noncompetitive inhibitor of the NMDA receptors. 
Excessive activation of AMPA/kainate receptors can 
cause membrane depolarization, followed by expelling 
Mg2+block of NMDA receptor, allows a large influx of 
Ca2+through NMDA-gated channels (8-11). 
Calcium is essential intracellular ion for proper 
function of neuronal cells. Several studies indicate that 
calcium could stimulate enzymes in mitochondria to 
increase the ATP synthesis. On the other hand, 
mitochondria have a pivotal role in the regulation of 
neuronal calcium signaling, neuronal calcium 
homeostasis, and calcium-dependent exocytosis. At high 
intracellular Ca2+levels mitochondria cease respiration 
and evoking the generation of reactive oxygen species 
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(1,7,12,13). However, the high levels of neuronal 
cytoplasmic calcium can activate several hydrolytic 
enzymes such as lipases, proteases, endonucleases. The 
stimulation of intracellular processes will increase the 
oxygen demand that further aggravates the hypoxia. All 
these events result in apoptotic or necrotic cell death 
(1,14).  
Glutamate excitotoxicity and mitochondrial 
dysfunction have been linked to many human disease 
states such as stroke and chronic neurodegenerative 
disorders like Parkinson and Alzheimer (15-17). 
Therefore, prevention of the consequences of ischemic 
cell damage may provide effective therapeutic strategies. 
Recently, a porphyrin-attached fullerene-C60 
nanoparticle of magnetic magnesium (25Mg PMC16) 
which possesses cationite properties has been 
designed for the correction of ATP synthesis in oxygen-
depleted cells (18,19). This low toxic nanoparticle with 
amphiphilic membranotropic properties is the iron 
containing porphyrin monoadduct of a classical 
Buckminsterfullerene, buckminsterfullerene (C60)-2-
(butadiene-1-yl)-tetra (o-γ-aminobutyryl-o-phthalyl) 
ferroporphyrin, named ‘‘Porphylleren-MC16’’ or, in 
brief, PMC16 (18). This smart nanoparticle has unique 
physical and chemical properties. The non-allergic, anti-
inflammation and high biocompatibility of its 
components make PMC16 suitable for pharmacological 
studies (18). The 25Mg isotopes that released by this 
nanoparticle activate both substrate and oxidative 
phosphorylation pathways and stimulate the production 
of ATP in oxygen-depleted cells (18,20). Furthermore, 
the protective effects of magnesium salts against brain 
ischemia have been shown in several studies. These 
studies indicate that magnesium could attenuate 
neuronal death by a various mechanism including 
inhibition of NO production, inhibition of NMDA 
glutamate receptors and the regulation of 
Ca2+accumulation (20-23). 
In this study the protective effect of 25Mg PMC16 on 
PC12 cells, a rat pheochromocytoma cell line, against 
oxygen-glucose deprivation/reperfusion induced 
neurotoxicity has been studied. 
  
Materials and Methods 
 
Chemicals and reagents 
25MgPMC16 was received from the Semenov 
institute (Russian Academy of Sciences) and dissolved 
in 1 mM Na-EDTA and 15 mM Na phosphate buffer at a 
concentration of 1 mg/ml. The solution was further 
diluted with RPMI to obtain the desired concentrations. 
The highest concentration of EDTA in each well of the 
plates was lower than 0.1% to prevent the significant 
cytotoxic effects on the PC12 cells. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 
(MTT), MK-801 were purchased from Sigma Chemical 
Co. (St. Louis, MO, USA). Cell culture media RPMI-
1640 and Dulbecco’s modified Eagle’s medium 
(DMEM), Fetal Bovine Serum (FBS), Horse Serum 
(HS), and penicillin-streptomycin were purchased from 
GIBCO BRL. 
 
Cell line 
PC12 cells were obtained from the Pasteur institute 
of Iran (Tehran, Iran) and were grown in RPMI-1640, 
supplemented with 10% FBS (heat-inactivated), 5% HS 
(heat-inactivated), 100 IU/ml penicillin and 100 µg/ml 
streptomycin, in a humidified incubator aerated with 5% 
CO2 in air at 37°C. The cells were subcultured twice a 
week by gentle scraping and cultured at a density of 6-
8×105cells/ml in 96-wells plates. Cells were used for 
experiments 24 h after seeding. 
 
Drug administration and oxygen-glucose deprivation 
Cells were treated 24 h before oxygen-glucose 
deprivation with 25Mg PMC16 at the concentrations of 
10−4, 10−3, 10−2, and 10−1 mg/ml. These concentrations 
were chosen based on the results of preliminary 
experiments. To investigate the effects of glutamate 
receptor inhibitors on oxygen-glucose deprivation-
induced cell death, MK801, a non-competitive 
antagonist of the NMDA receptor, was added to the 
medium 24 h before the oxygen-glucose deprivation.  
The model of oxygen-glucose deprivation was 
performed as described previously (24). Briefly, the 
culture medium was replaced with glucose/glutamine-
free DMEM and was exposed to hypoxia for 30, 60 and 
120 minutes in a small anaerobic chamber previously 
filled with 95% (v/v) N2 and 5% (v/v) CO2 at 37°C. To 
terminate the oxygen-glucose deprivation, the chamber 
was opened, and the medium was replaced with RPMI-
1640 and the cultures were then placed in an incubator 
with 5% CO2 for 24 h. 
 
Analysis of cell viability 
Cell viability was monitored using the colorimetric 
MTT assay as previously described (25). Cells were 
incubated with 5 mg/ml MTT in RPMI, at 37°C under 
5% CO2 for 3 h. The blue formazan reduction product, 
produced by the action of succinate dehydrogenase in 
living cells, was dissolved in 100 µl dimethylsulfoxide 
(DMSO), and the optical density was read at 570 nm 
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using a Dynex MMX microplate reader (Dynex, 
Richfield, MN, USA). Data were expressed as the 
percentage of viable cells in oxygen-glucose 
deprivation-exposed plates compared with the control 
normoxic plates determined by MTT reduction. 
 
Statistical analysis 
Data were expressed as means±S.E.M. The 
significance of differences between means was 
determined using Student’s t-test. The P<0.05 were 
considered significant. 
 
Results 
 
The effects of 25MgPMC16 on oxygen-glucose 
deprivation/24h reperfusion-induced cell injury on 
PC12 cell line 
We examined the effects of 25Mg PMC16 on 30, 60 
and 120 min oxygen-glucose deprivation/24h 
reperfusion induced cell injury in PC12 cells. Cell 
cultures were pretreated with 25Mg PMC16, 24 hours 
before exposure to 30, 60 and 120 min of oxygen-
glucose deprivation. 
Pretreatment of cell cultures with 25Mg PMC16 
(10−4, 10−3, 10−2, and 10−1 mg/ml) 24 h before exposure 
to 30,60 and 120 min oxygen-glucose deprivation 
significantly increased the percentage of viable cells in a 
concentration-dependent manner (Figures 1-3). 
 
 
Figure 1. The effects of 25Mg PMC16 (10−4, 10−3, 10−2, and 10−1 mg/ml) and MK-801 (10 µM) during 30 min oxygen-glucose deprivation/24 h 
reperfusion- induced cell injury on PC12 cell culture. The dashed bar shows the drug group and the black bar shows the control group. Optical density 
at 570 nm corresponds to the blue formazan reduction product which is produced by the action of mitochondrial succinate dehydrogenase in living 
cells and correlates to cell viability. Data are expressed as the percentage of viable cells in oxygen-glucose deprivation-exposed plates compared with 
control normoxic plates (100%). **P< 0.005, ***P< 0.0005 
 
 
Figure 2. The effects of 25Mg PMC16 (10−4, 10−3, 10−2, and 10−1 mg/ml) and MK-801 (10 µM) during 60 min oxygen-glucose deprivation/24 h 
reperfusion- induced cell injury on PC12 cell culture. The dashed bar shows the drug group and the black bar shows the control group. Optical density 
at 570 nm corresponds to the blue formazan reduction product which is produced by the action of mitochondrial succinate dehydrogenase in living 
cells and correlates to cell viability. Data are expressed as the percentage of viable cells in oxygen-glucose deprivation-exposed plates compared with 
control normoxic plates (100%). *P<0.05, ***P<0.0005 
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Figure 3. The effects of 25Mg PMC16 (10−4, 10−3, 10−2, and 10−1 mg/ml) during 120 min oxygen-glucose deprivation/24 h reperfusion- induced 
cell injury on PC12 cell culture. The dashed bar shows the drug group and the black bar shows the control group. Optical density at 570 nm 
corresponds to the blue formazan reduction product which is produced by the action of mitochondrial succinate dehydrogenase in living cells and 
correlates to cell viability. Data are expressed as the percentage of viable cells in oxygen-glucose deprivation-exposed plates compared with control 
normoxic plates (100%). **P<0.005, ***P<0.0005 
 
The effects of MK-801 on oxygen-glucose 
deprivation/24h reperfusion-induced cell injury on 
PC12 cell line 
MK-801, a non-competitive NMDA receptor 
antagonist (10 µM), significantly increased cell viability 
in 30 min oxygen-glucose deprivation (Figure 1). MK-
801(10 µM) partially increased cell viability in 60 min 
oxygen-glucose deprivation (Figure 2). 
So it seems that activation of NMDA receptors is the 
major cause of cellular damage during 30 or 60 minutes 
of OGD/R. It also shows that the pathway followed by 
OGD/R is the same pathway as excitotoxicity (that has 
been proven in various studies) (9,26). 
During 120 minutes OGD/R, MK801 did not have 
any significant inhibitory effect on cell death. It shows 
the role of glutamate-induced cell death just at the early 
stage of excitotoxicity cascade.  
 
Discussion 
 
In the current study, we examined whether 
25MgPMC16 can protect PC12 cells against oxygen-
glucose deprivation. PC12 cells are a rat 
Pheochromocytoma cell line represents as a suitable 
model of neurons (26,27). We used oxygen glucose 
deprivation as a well-characterized in vitro model for the 
induction of neuronal cell injury. Our results indicated 
that 25MgPMC16 could effectively protect the PC12 
cells against cell death induced by oxygen-glucose 
deprivation/reperfusion in all three time schedules. We 
observed that when cells exposed to 30,60 and 120 
minutes oxygen-glucose deprivation/reperfusion the 
drug dramatically suppressed the PC12 cell death in a 
concentration-dependent manner. MK-801 an antagonist 
of glutamate NMDA receptors significantly attenuated 
30 minutes oxygen-glucose deprivation/reperfusion 
induced neurotoxicity but partially increased cell 
viability in 60 min oxygen-glucose deprivation. 
Due to cationic properties of 25MgPMC16, this smart 
nanoparticle has the ability to deliver its magnetic 
magnesium only in an acidosis condition which is a 
natural consequence of any type of hypoxia (18). As 
mentioned in the introduction, 25Mg2+ activates both 
pathways of ATP synthesis (18,28). Magnesium has a 
catalytic effect and possible structural role in creatine 
kinase and Mg-containing enzymes of mitochondrial 
respiratory chain (19). Beside the remarkable 
improvement in ATP production and regulation of Ca2+ 
accumulation, magnesium is involved in the facilitation 
of Na+/K+ ATPase function, ion gradients stabilization, 
protein synthesis and maintaining membrane integrity 
(23,29). 
The neuroprotective effect of magnesium has been 
shown in many experimental studies. It has been shown 
that magnesium sulfate reduces cerebral injury in 
transient cerebral ischemia in rats (30). Another study 
suggested that treatment with MgCl2 is effective in the 
attenuating of the neurological damage in experimental 
rat brain injury (29). Also, it has been shown that the 
neuroprotective effect of magnesium is due to its 
inhibition of NO production in fetal hippocampal slices 
after oxygen-glucose deprivation (21). In addition, 
previous studies indicated that under ischemic 
conditions, magnesium could attenuate the neuronal cell 
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death by inhibition of neurotransmitter release and 
anoxia-induced depolarization (22,30,31). However, 
Muir et al., in a randomized controlled trial, examined 
the effect of intravenous magnesium sulfate in patients 
with acute stroke. The results indicated that magnesium 
given within 12 h of acute stroke did not reduce the 
death or disability significantly (32). According to our 
results, the protective effect of 25MgPMC16 on PC12 
cell death during oxygen-glucose/deprivation might be 
partially due to the release of its 25Mg2+ in acidosis 
condition of ischemia.  
In previous studies in hypoxic cardiopathies, 
25MgPMC16 protected myocardium cells of serious 
damage of hypoxia. 25Mg released by these 
nanoparticles stimulated the production of ATP in 
oxygen-depleted cells (18,33,34). In another study, it has 
been shown that 25MgPMC16 could protect the rat 
lymphocytes against chemical hypoxia induced by 
energy metabolism inhibitors (19). Recently, in 
experimental diabetic neuropathy, 25MgPMC16 
protected Dorsal Rat Ganglion (DRG) neurons from cell 
injury and also caused significant changes in oxidative 
stress biomarkers in comparison to diabetic neuropathy 
control groups (20). Measurements of ATP production 
and ADP/ATP in the presence of 25MgPMC16 indicated 
that this nanoparticle increases the total rate of ATP 
synthesis via substrate phosphorylation and oxidative 
phosphorylation in mitochondria; therefore 25MgPMC16 
could protect the heart muscle cells and DRG neurons 
from cell death (18,20).  
According to our results, it could be suggested that at 
the early stage of excitotoxicity, 25MgPMC16 could 
decrease the extracellular glutamate by over production 
of ATP synthesis via the improvement of ATP-
dependent glutamate transporters function. On the other 
hand, the excessive cytoplasmic Ca2+ levels, due to Ca2+ 
influx, is sequestered into the mitochondria and 
decreases the electrochemical gradient, followed by a 
decline in ATP synthesis. Concurrently, mitochondria 
should extrude excessive calcium from the membrane 
which is an ATP dependent process (7,35). Primary 
inhibition of the mitochondrial respiratory chain 
indirectly induced NMDA receptor stimulation, which is 
termed as secondary excitotoxicity (11). It is likely that 
25MgPMC16 compensate ATP deficiency and supply 
energy required to maintain ionic gradient so that Ca2+ 
pump can push out extra Ca2+ and might prevent the 
occurrence of the secondary excitotoxicity.  
Oxidative stress is a contributing factor in 
excitotoxicity through the generation of oxygen radicals 
and plays a critical role in the progression of 
neurodegenerative diseases (36-39). It has been 
demonstrated that fullerene derivatives are excellent 
antioxidant agents and characterize as radical sponges 
against excitotoxic cell death (40-43). They could 
decrease the toxicity of free radical on the neuronal 
tissue (42). On the other hand, Mg2+ competes with 
calcium ions for binding sites on mitochondrial 
membrane, that resulting in a reduction of Ca2+-induced 
mitochondrial reactive oxygen species generation 
(44,45). Taking together, it could be suggested that, 
25MgPMC16, with Mg2+ and fullerene C60 structure, 
could attenuate cell injury-induced oxidative stress. 
According to our results, 25MgPMC16 could 
significantly protect cells against cell death, even during 
the long periods of oxygen-glucose 
deprivation/reperfusion (120 min). It seems that the 
long-lasting effect of PMC16 with magnetic magnesium 
is due to its unique structure, including magnesium, 
porphyrin, and C60 fullerene. Porphyrin domain of 
PMC16 has high affinity to receptors located in the 
external membrane of the mitochondria, and C60 
fullerene, selectivity accumulate inside mammalian 
mitochondria (18, 20). 
In conclusion, 25MgPMC16 nanoparticles could 
affect in the several parts of excitotoxicity cascade 
thereby could protect cells from cell death. dPossible 
mechanism of the protective effect of 25MgPMC16 
could be summarized as target delivery of magnesium, 
positive role in the improvement of ATP production and 
antioxidant properties of its components. These findings 
may be useful for the development of a new generation 
of drugs against stroke and chronic neurodegeneration 
disorders. 
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